Suppliers / Interquim

Interquim

Mexico 2 duplicate records merged Updated 9 July 2026

Interquim is an API manufacturer based in Mexico. It holds 20 active US drug master files across a filed portfolio of 22 molecules. Its GMP standing is certified by COFEPRIS (MX) and US FDA. Its most recent recorded inspection, by US FDA, closed on 6 September 2024 as VAI.

20
active US DMFs
0
valid CEPs
3
registered plants 2 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
2 of 2 confirmed
Inspections
8 of 8 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 6 September 2024 VAI US FDA
  • 16 December 2022 NAI US FDA
  • 27 September 2019 VAI US FDA
  • 20 December 2018 VAI US FDA
  • 2 June 2017 VAI US FDA
  • 6 May 2016 OAI US FDA
  • 19 June 2015 VAI US FDA
  • 11 October 2013 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Spain, Spain 3002807304
Mexico, Mexico 3005170172
Cuautitlán Izcalli, Mexico Not on file

What they file, and where

Molecule Regulators Docs
Imiquimod SFDA (Saudi Arabia), US FDA 3
Paliperidone SFDA (Saudi Arabia), US FDA 3
Aripiprazole US FDA 2
Celecoxib SFDA (Saudi Arabia), US FDA 2
Ozenoxacin SFDA (Saudi Arabia), US FDA 2
Rivastigmine SFDA (Saudi Arabia), US FDA 2
Aripiprazole Lauroxil US FDA 1
Ciclopirox US FDA 1
Diacerein SFDA (Saudi Arabia) 1
Diosmin SFDA (Saudi Arabia) 1
Show all 22 molecules on file
Edaravone US FDA 1
Ferric Carboxymaltose US FDA 1
Lifitegrast US FDA 1
Rasagiline SFDA (Saudi Arabia) 1
Risperidone US FDA 1
Rivaroxaban US FDA 1
Roflumilast US FDA 1
Rotigotine US FDA 1
Sertaconazole US FDA 1
Solifenacin Succinate US FDA 1
Telmisartan SFDA (Saudi Arabia) 1
Tolterodine US FDA 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
COFEPRIS (MX) None 2
US FDA None 1

Comparing suppliers?

Choose your molecules and target markets. Interquim comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • 4 active litigation matters are on record.
  • The most recent inspection outcome was VAI, on 6 September 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates